VivoSeq
Other

Proliferative Vitreoretinopathy

15

Pipeline Programs↗

5

Active Trials↗

6

Companies Involved↗

Proliferative Vitreoretinopathy is an emerging landscape with 15 programs across 6 companies. The most active players are Meitheal, Astellas, Regeneron. 5 therapies are approved with 2 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

44/100

Pipeline Velocity

11/100

Mech. Concentration

25/100

Completion Rate

86/100

Attrition Rate

7/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

M

Meitheal

1 program

Phase 1Astellas logo

Astellas

1 program

Phase 1Regeneron logo

Regeneron

1 program

Phase 2F

Falcon

1 program

Phase 2A

Aldeyra Therapeutics, Inc.

1 program

Phase 3Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals

2 programs

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

88%

Small molecule

14 of 16 classified programs — the dominant modality here.

13%ALL OTHERSMonoclonal antibody16%Protein / enzyme16%

Small molecule leads; the ring shows all 16 classified programs, each share of the total. Modality classified for 100% of 16 pipeline programs.

Analysis

Trial Status

15

clinical trials

Completed6 · 40%
Unknown status3 · 20%
Recruiting2 · 13%
Not yet recruiting2 · 13%
Withdrawn1 · 7%
Enrolling by invitation1 · 7%

Clinical Trials

Trial Activity

15 trials

Prevention of ProliFerative Vitreoretinopathy with Intravitreal MethotreXate in Primary Retinal DEtachment Repair (FIXER) Trial
Recruiting·CCincinnati Eye Institute, Southwest Ohio·Phase 2·NCT06541574·860 enrolled
Topical Netarsudil for the Prevention of Proliferative Vitreoretinopathy in Patients With Retinal Detachment
Recruiting·MMassachusetts Eye and Ear Infirmary·Phase 1/2·NCT06033703·48 enrolled
Intravitreal Topotecan for Prevention or Treatment of Proliferative Vitreoretinopathy in Retinal Detachment
Not yet recruiting·UUnity Health Toronto·Phase 2·NCT06818721·394 enrolled
The Safety and Efficacy of Intravitreal Topotecan for the Treatment of Proliferative Vitreoretinopathy
Not yet recruiting·MMassachusetts Eye and Ear Infirmary·Phase 1·NCT06425419·50 enrolled
Identification of Imaging Biomarkers and Predictive Modelling of Proliferative Vitreoretinopathy Using Deep Learning.
Enrolling by invitation·UUniversity College, London·N/A·NCT07682025·100 enrolled
Isotretinoin for Proliferative Vitreoretinopathy
Completed·—·Phase 4·NCT01445028·109 enrolled
Triamcinolone Acetonide in Silicone-Filled Eyes as Adjunctive Treatment for Proliferative Vitreoretinopathy
Completed·SShahid Beheshti University of Medical Sciences·Phase 3·NCT00373282
The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy
Completed·AAldeyra Therapeutics, Inc.·Phase 3·NCT04136366·106 enrolled
Intravitreal Infliximab for Proliferative Vitreoretinopathy
Completed·—·Phase 2·NCT04891991·66 enrolled
Adrenocorticotropic Hormone (ACTH) for Post-op Inflammation in Proliferative Vitreoretinopathy (PVR)
Completed·JJohns Hopkins University·Phase 1·NCT03727776·11 enrolled
Dacorin for Proliferative Vitreoretinopathy
Completed·—·Phase 1/2·NCT02865031·15 enrolled
Methotrexate For The Prevention and Treatment of Proliferative Vitreoretinopathy in Pediatric Patients
Withdrawn·SStanford University·Phase 1·NCT04830878
Repeated Methotrexate for Proliferative Vitreoretinopathy Grade C
Unknown status·SShahid Beheshti University of Medical Sciences·Phase 2/3·NCT04482543·74 enrolled
Oral Colchicine Combined With Intravitreal Infusion of Dexamethasone, LMW Heparin and 5-FU for Management of Proliferative Vitreoretinopathy (PVR)
Unknown status·SShahid Beheshti University of Medical Sciences·Phase 3·NCT00370760
Intravitreal Aflibercept for the Prevention of Proliferative Vitreoretinopathy Following Retinal Detachment Repair
Unknown status·—·Phase 2·NCT04580147·150 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)